Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kala Pharmaceuticals Inc.
DescriptionSorafenib delivered using mucus-penetrating nanoparticles
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat ophthalmic diseases
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today